ArticlePloS one2013
TAILOR: transgene activation and inactivation using lox and rox in zebrafish.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- A noninvasive photoactivatable split-Cre recombinase system for genome engineering in zebrafish.iScience · 2024Article
- Fate-Mapping Macrophages: From Ontogeny to Functions.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Review
- Zebrafish Models of Paediatric Brain Tumours.International journal of molecular sciences · 2022Review
- Cre/eLife · 2022Article
- One-step efficient generation of dual-function conditional knockout and geno-tagging alleles in zebrafish.eLife · 2019Article
- Luminal-contact-inhibition of epithelial basal stem cell multipotency in prostate organogenesis and homeostasis.Biology open · 2019Article
- A single reporter mouse line for Vika, Flp, Dre, and Cre-recombination.Scientific reports · 2018Article
- A knock-in allele of En1 expressing dre recombinase.Genesis (New York, N.Y. : 2000) · 2016Article
- Review
- Novel Heterotypic Rox Sites for Combinatorial Dre Recombination Strategies.G3 (Bethesda, Md.) · 2015Article
- Increased functional protein expression using nucleotide sequence features enriched in highly expressed genes in zebrafish.Nucleic acids research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The ability to achieve precisely tailored activation and inactivation of gene expression represents a critical utility for vertebrate model organisms. In this regard, Cre and other site-specific DNA recombinases have come to play a central role in achieving temporally regulated and cell type-specific genetic manipulation. In zebrafish, both Cre and Flp recombinases have been applied for inducible activation, inactivation and inversion of inserted genomic elements. Here we describe the addition of Dre, a heterospecific Cre-related site-specific recombinase, to the zebrafish genomic toolbox. Combining Dre-based recombination in zebrafish with established Cre/lox technology, we have established an effective strategy for transgene activation and inactivation using lox and rox (TAILOR). Using stable transgenic lines expressing tamoxifen-inducible CreER(T2) and RU486-inducible DrePR fusions, we demonstrate that Cre and Dre retain non-overlapping specificities for their respective lox and rox target sites in larval zebrafish, and that their combinatorial and sequential activation can achieve precisely timed transgene activation and inactivation. In addition to TAILOR, the successful application of Dre/rox technology in zebrafish will facilitate a variety of additional downstream genetic applications, including sequential lineage labeling, complex genomic rearrangements and the precise temporal and spatial control of gene expression through the intersection of partially overlapping promoter activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.